Immunogenic composition comprising (i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (ii) an antigen, and (iii) an aluminum-containing adjuvant； wherein the aluminum-containing adjuvant is selected from aluminum hydroxide, aluminum oxyhydroxide and aluminum hydroxyphosphate； and wherein the compound of Formula (I) is a TLR7 agonist: wherein: R1 is H, C1-C6 alkyl, -C (R5) 2OH, -L1R5, -L1R6, -L2R5, -L2R6, - OL2R5 or -OL2R6； L1 is -C (O) - or -O-； L2 is C1-C6 alkylene, C2-C6 alkenylene, arylene, heteroarylene or - ((CR4R4) pO) q (CH2) p-, in which C1-C6 alkylene and C2-C6 alkenylene of L2 are optionally substituted with 1 to 4 fluoro groups； each L3 is independently selected from C1-C6 alkylene and - ((CR4R4) pO) q (CH2) p-, wherein the C1-C6 alkylene of L3 is optionally substituted with 1 to 4 fluoro groups； L4 is arylene or heteroarylene； R2 is H or C1-C6 alkyl； R3 is selected from C1-C4 alkyl, -L3R5, -L1R5, -L3R7, -L3L4L3R7, -L3L4R5, -L3L4L3R5, -OL3R5, -OL3R7, -OL3L4R7, -OL3L4L3R7, -OR8, -OL3L4L-OL5 (R5) 2OH； each R4 is independently selected from H and fluoro； R5 is -P (O) (OR9) 2； R6 is -CF2P (O) (OR9) 2 or -C (O) OR10； R7 is -CF2P (O) (OR9) 2； R8 is H or C1-C4 alkyl； each R9 is independently selected from H and C1-C6 alkyl； R10 is H or C1-C4 alkyl； each p is independently selected from 1, 2, 3, 4, 5 and 6, and q is 1, 2, 3 or 4； provided that when R3 is C1-C4 alkyl or -OR8, R1 is -C (R5) 2OH, -L1R5, -L1R6, -L2R5, -L2R6, -OL2R5, or -OL2R6, where R6 is -CF2P (O) (OR9) 2.Composición inmunógena que comprende (i) un compuesto de Fórmula (I), o una sal del mismo farmacéuticamente aceptable, (ii) un antígeno, y (iii) un adyuvante que contiene aluminio； en la que el adyuvante que contiene aluminio está seleccionado de entre hidróxido de aluminio, oxihidróxido de aluminio e hidroxifosfato de aluminio； y en la que el compuesto de Fórmula (I) es un agonista de TLR7: en la que: R1 es H, alquilo C1-C6, -C(R5)2OH, -L1R5, -L1R6, -L2R5, -L2R6, -OL2R5
